All sponsors

Shanghai JMT-Bio Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS25
PHASE 3 / 2-315
RECRUITING10
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO8%

Delay Index: of 12 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Shanghai JMT-Bio Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
JMT101 Injection
NCT06391944
P2Active, not recruitingLocal Advanced or Metastatic NSCLC; Harboring EGFR Common Mutation1612023-05-17
Recombinant Humanized Bispecific antibody against HER2,KN026
NCT05838066
P3RecruitingFirst-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer8802025-07-31
KN026/Placbo Injection
NCT05427383
P2/3RecruitingStomach Cancer2862025-11
Mitoxantrone Hydrochloride Liposome
NCT06892431
P2Not yet recruitingRecurrent or Metastatic Nasopharyngeal Cancer; Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy1502025-12-31
JMT101
NCT06319313
P2/3Not yet recruitingSquamous Cell Non-small Cell Lung Cancer5342026-07-01
phase Ib/Ⅱa st
NCT07140809
P1/2RecruitingHypertriglyceridemia482026-07-31 (+2 mo)
JMT101
NCT06735391
P3RecruitingLocally Advanced or Metastatic Non-squamous NSCLC; Harboring EGFR Sensitive Mutations NSCLC5162026-09-30
JSKN003
NCT06846437
P3RecruitingUnrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants2282026-10-13
JMT108
NCT07280832
P1/2RecruitingUnresectable Locally Advanced or Metastatic Melanoma; Unresectable Locally Advanced or Metastatic Urinary Tract Tumors5002026-11-30
Neo-Healer
NCT06747338
P3Active, not recruitingEarly or Locally Advanced HER2-positive Breast Cancer5202026-12-16
JMT101 Injection
NCT06380348
P3Not yet recruitingLocal Advanced or Metastatic NSCLC3982027-03-26
JMT601 Injection
NCT07029139
P2Not yet recruitingPrimary Membranous Nephropathy1562027-04-01
JSKN003
NCT07545044
P2Not yet recruitingHER2-positive Recurrent or Metastatic Breast Cancer602027-05-29
JMT103
NCT06221072
P3Not yet recruitingImaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors13602027-05-31
JMT101
NCT07134205
P3Not yet recruitingMetastatic Colorectal Cancer (mCRC)2522027-06-01
JMT203 Injection
NCT06868849
P1/2RecruitingNon Small Cell Lung Cancer; Pancreatic Cancer3072027-08-14 (+15 mo)
JSKN003
NCT07384377
P3Not yet recruitingHER2-positive Colorectal Cancer1232027-11-30
Glumetinib
NCT06829459
P3RecruitingNon-Small Cell Lung Cancer3502028-02-15
JMT108
NCT06877650
P1/2RecruitingAdvanced Malignant Tumors4362028-03-30
Narlumosbart
NCT05813665
P3Not yet recruitingGiant Cell Tumor of Bone1462028-06
JSKN003
NCT06998771
P2Not yet recruitingHER2-positive Gastric Cancer1532028-06-30
Glumetinib Tablets
NCT06908772
P2/3Not yet recruitingRecurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression3902028-12-31
SYS6090 + pemetrexed + platinum-based chemotherapy
NCT07472647
P1/2Not yet recruitingNon-Small Cell Lung Cancer; Small Cell Lung Cancer5962029-02-28
KN026
NCT07332533
P2/3Not yet recruitingHER2-positive Gastric Cancer4902032-06-30
KN026
NCT07441460
P3RecruitingResectable HER2-positive Breast Cancer18002034-08-07